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AbstrACt
Introduction Acute brain injury is a challenging 
public health problem worldwide. Elevated intracranial 
pressure is a common complication after acute brain 
injury. Hyperosmolar therapy is one of the main 
therapeutic strategies for the management of intracranial 
hypertension. This study protocol outlines an umbrella 
review of meta- analyses which will investigate the benefits 
and harms of hyperosmolar therapy routinely used for the 
management of acute brain injury in the intensive care.
Methods and analysis We will search PubMed/
MEDLINE, EMBASE and the Cochrane Database of 
Systematic Reviews. We will include meta- analyses of 
primary research studies (eg, randomised controlled 
trials, observational studies or both) that evaluate one or 
more hyperosmolar solutions (including hypertonic saline 
and/or mannitol) for the treatment of adult patients with 
acute brain injury of any severity. Two researchers will 
independently screen all citations, full- text articles and 
abstract data. Potential conflicts will be resolved through 
discussion with a third researcher. Primary outcomes 
will be mortality and neurological outcomes at discharge. 
Secondary outcomes will include control of intracranial 
pressure, cerebral perfusion pressure, length of stay 
(in hospital an intensive care unit) and any adverse 
event. Quality of the included meta- analyses will be 
assessed using the AMSTAR-2 tool. An overall summary 
of methods and results will be performed using tabular 
and graphical approaches and will be supplemented by 
narrative description. We will analyse whether published 
meta- analyses present an outline of available evidence 
(eg, cited, described and discussed any previous meta- 
analysis). Where objectives from two or more meta- 
analyses overlap, we will assess the causes of any noted 
discrepancies between meta- analyses.
Ethics and dissemination No ethical approval will be 
required. Findings from this study will be published in 
a peer- reviewed journal. All data will be deposited in a 
cross- disciplinary public repository.
PrOsPErO registration number CRD42019148152.
IntrOduCtIOn
Acute brain injury has become a chal-
lenging public health problem worldwide,1–3 
resulting in a large burden of disease in terms 
of premature death and disability. Compli-
cations after acute brain injury cause poor 
outcomes and enormous losses to individuals, 
families and communities. Elevated intracra-
nial pressure (ICP) is a common problem in 
intensive care units (ICUs), being a poten-
tially devastating complication of acute brain 
injury. Prevention and control of elevated 
ICP are the cornerstones of treatment for 
these patients,4–6 as uncontrolled hyperten-
sion worsens brain damage and remains the 
most common cause of death after the injury.
Several strategies are recommended for the 
treatment of elevated ICP in adult patients 
with acute brain injury.7–9 Currently, hyper-
osmolar therapy with mannitol or hypertonic 
saline solution is the main therapeutic strategy 
for the management of intracranial hyperten-
sion and cerebral oedema.9 Although hyper-
osmolar therapy has been used extensively 
in routine clinical practice,10–12 significant 
strengths and limitations of this study
 ► This will be the first umbrella review to systemati-
cally identify and evaluate the quantity, validity and 
credibility of published meta‐analyses on hyperos-
molar therapy for acute brain injury.
 ► Our literature review will be expansive, including 
meta- analyses of randomised controlled trials, ob-
servational studies or both.
 ► There may be variability in how treatment inter-
ventions and outcomes are reported in published 
meta- analyses, which may pose a challenge in the 
qualitative (narrative) synthesis.
 ► There may be a paucity in patient- important out-
comes reported in the published meta- analyses 
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controversy regarding the choice of hyperosmolar agent 
and dosing exists.
Systematic reviews with meta- analyses are prominent 
tools to guide healthcare decisions and inform research 
agendas. A growing number of systematic reviews and 
meta- analyses aiming to evaluate the effects of hyperos-
molar solutions in acute brain injury have been published 
showing inconsistent results.13–23 As the number of 
published meta- analyses increases, conflicts and divergent 
conclusions among them can emerge producing difficul-
ties for decision makers who rely on these studies.24 In 
addition, many meta- analysis authors may not discuss the 
results of previous meta- analyses and systematic reviews.25 
This situation can be confusing for readers and knowl-
edge users, may contribute to unnecessary duplications 
of meta- analysis26–28 and possibly cause waste in research 
planning, conduct and reporting.29 30
This study has been designed to answer the following 
primary research question: what is the effectiveness and 
safety of hyperosmolar therapy (mannitol and hypertonic 
saline) routinely used for the management of acute brain 
injury in intensive care? There are three aims within the 
planned study. The first aim will be to evaluate the quan-
tity, validity and credibility of the evidence from existing 
systematic reviews and meta‐analyses with regard to the 
benefits and harms of hyperosmolar therapy for acute 
brain injury. The second aim will be to provide a robust 
assessment of the evidence in this area using a revised 
and improved quality assessment tool: AMSTAR-2.31 The 
third aim will be to investigate whether published meta- 
analyses present an outline of available evidence by refer-
ring to previous meta- analyses and systematic reviews, and 
compare and contrast findings across overlapping meta- 
analyses on the same topic.
MEthOds And AnAlysIs
This review protocol is part of an evidence synthesis project 
on the comparative effectiveness and safety of hyperos-
molar therapy in neurocritical care. We will conduct an 
umbrella review (or ‘overview of reviews’),32 33 which is 
the systematic collection and assessment of multiple 
systematic reviews and meta‐analyses carried out in a 
specific research topic. This study protocol has been 
registered within PROSPERO database (registration 
number: CRD42019148152), the Open Science Frame-
work (https:// osf. io/ mcqpv), and has been prepared 
in consultation with the reporting guidance in the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses Protocols34 35 (see online supplementary 
appendix 1 for the checklist). Methods have been chosen 
in consultation with methodological work,32–41 including 
the Cochrane Handbook’s chapter on methods for ‘over-
views of reviews’.33
Eligibility criteria
Detailed eligibility criteria have been developed following 
the population, interventions, comparators, outcomes 
and study design format and are described below.
Population
This study will include adult patients over the age of 
18 years admitted to an ICU with an acute primary neuro-
logical diagnosis (that is, traumatic brain injury, stroke 
or intracerebral haemorrhage) of any severity. Patients 
with disseminated cerebral disorders (such as meningitis, 
encephalitis, acute hepatic failure and neoplasms) will be 
excluded.
Interventions and comparators
The intervention group will be intravenous administra-
tion of hyperosmolar therapy routinely used in the ICU, 
including hypertonic saline at any dose (eg, 3%, 7.5% or 
23.4% sodium chloride) and mannitol at any dose (e.g. 
≥20% mannitol) for any duration. The control group 
could be placebo- controlled, standard of care, no therapy 
and different therapy (eg, alternative fluid therapy such 
as 0.9% sodium chloride (normal saline), ≤0.45% sodium 
chloride (hypotonic saline), 5% dextrose, Ringer’s lactate, 
Hartmann’s solution). Treatment comparisons of interest 
will include hyperosmolar therapy in monotherapy and/
or combination therapy regimens against each other or 
against an alternative control group.
Outcomes
Results on all primary and secondary outcomes of the 
included systematic reviews and meta- analyses will be 
reported. However, we will define the following primary 
and secondary outcomes for this study. The primary 
outcomes will be patient- important outcomes including 
mortality from all causes (defined as 90 day mortality, if 
not available, 30- day ICU or hospital mortality, whichever 
was longest) and neurological outcomes at discharge 
(as reported by authors of included studies, eg, Glasgow 
Outcome Scale, extended Glasgow Outcome Scale or 
modified Rankin Scale). The secondary outcomes will 
be ICP (mm Hg), cerebral perfusion pressure (mm Hg), 
any adverse events (as reported by authors of included 
studies) and important health services use measures such 
as length of hospital stay and length of ICU stay (both in 
days).
Study design
We will consider published articles of completed system-
atic reviews with meta‐analysis of randomised controlled 
trials, observational studies (eg, cohort studies, case- 
control studies) or both. We will include articles that 
explicitly stated methods to identify studies (eg, a search 
strategy), explicitly stated methods of study selection 
(eg, eligibility criteria and selection) and explicitly 
described methods of quantitative data synthesis (eg, at 
least reported a meta- analysis summarising the results 
of several studies into a single estimate). To ensure as 
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meta- analysis, including updates of previous reviews with 
meta- analyses, and reviews with overlapping evidence 
base (eg, primary studies could appear within more than 
one included meta- analysis) will be eligible for inclusion. 
Only references published in English will be eligible as 
the vast majority of meta‐analyses are published in this 
language. Meta- analyses not reporting a systematic meth-
odology and narrative reviews will be excluded.
searching
We will search PubMed/MEDLINE, EMBASE and the 
Cochrane Database of Systematic Reviews (from January 
2000 onwards—considering the first Cochrane review on 
mannitol for acute traumatic brain injury was published 
in 200013). Intended date for the literature searches in 
PubMed/MEDLINE, EMBASE and the Cochrane Data-
base of Systematic Reviews will be 15 May 2020. The 
literature searches will be conducted by an experienced 
information specialist. The main literature search will be 
peer- reviewed by a senior health information specialist 
using the Peer Review of Electronic Search Strategies 
checklist.42 The draft search strategy can be found in 
online supplementary appendix 2. To ensure literature 
saturation, we will scan the reference lists of included 
meta- analyses, and relevant reviews and clinical practice 
guidelines identified through the search.
screening and selection procedure
All articles identified from the literature search will be 
screened by two researchers independently. First, titles 
and abstracts of articles returned from initial searches 
will be screened based on the eligibility criteria outlined 
earlier. Second, full texts will be examined in detail and 
screened for eligibility. Third, references of all consid-
ered articles will be hand- searched to identify any relevant 
report missed in the search strategy. Any discrepancies 
here and throughout will be resolved through consensus 
or recourse to a third researcher, if necessary. A flow chart 
showing details of studies included and excluded at each 
stage of the study selection process will be provided.
data collection
Data for each of the included meta- analysis will be 
abstracted by two researchers, independently, and poten-
tial conflicts will be resolved through discussion. We will 
use pre- designed forms that will be piloted initially on 
a small number of included articles. The data extracted 
from each article will be comprehensive in scope as 
we are addressing multiple review objectives. Informa-
tion of interest will include the following: first author, 
year of publication, reported a protocol, objective(s), 
reported strategies to search literature, number of data-
bases searched and date of last search, any restrictions 
(eg, language, geographic, or date), inclusion/exclusion 
criteria, intervention(s) of interest and comparators, 
patient population, main outcomes of interest, type of 
study designs included (eg, randomised controlled trials, 
observational studies, or both), number of included 
studies, number of studies reporting data for meta- 
analyses, effect metric(s) reported (eg, risk ratio, risk 
difference, standardised mean difference), methods 
to assess study quality/risk of bias, statistical methods 
to combine studies, summary meta- analytic estimates 
including heterogeneity measures, additional analyses 
(eg, subgroup analysis or sensitivity analysis), metabias 
assessment (eg, publication bias across studies), funding 
source and conflicts of interest, whether a previous meta- 
analysis was cited (eg, whether a reference to the earlier 
article was provided as part of the background and/
or rationale for the study), described (eg, whether any 
information about the results of the earlier article was 
provided) and discussed (eg, the results from the earlier 
article were related to the results or conclusions from the 
most recent study) by the published meta- analysis.
Quality assessment of meta-analyses
The methodological quality of meta- analyses will be eval-
uated using the AMSTAR-2 tool (see online supplemen-
tary appendix 3 for the checklist). This revised version 
of the original AMSTAR tool43 44 allows for the appraisal 
of systematic reviews and meta- analyses of randomised 
and non- randomised studies of healthcare interven-
tions.31 We will evaluate each included meta- analysis 
against the 16 items of the tool, and an overall rating 
will be assigned. Briefly, the AMSTAR-2 tool considers 
the following seven domains that can critically affect 
the validity of a meta- analysis and its conclusions: regis-
tration of the protocol prior to commencement of the 
review, adequacy of the literature search, justification for 
excluding individual studies, assessment of risk of bias of 
included studies, appropriateness of the meta- analytic 
methods, consideration of risk of bias when interpreting 
results and assessment of presence and impact of publi-
cation bias. Meta- analyses failing to meet any of the crit-
ical domains will be deemed to have a ‘critical flaw’ while 
non- fulfilment of the remaining items will be deemed 
a ‘non- critical weakness’. Meta- analyses with no ‘critical 
flaws’ will be considered either high or moderate quality 
depending on the number of ‘non- critical weaknesses’ 
(eg, high- quality meta- analyses have a maximum of one 
‘non- critical weaknesses’ and moderate- quality meta- 
analyses have more than one). Meta- analyses with one or 
more ‘critical flaws’ will receive a low or very low rating, 
respectively. The quality of meta- analyses will be evaluated 
by one researcher and verified by another. Disagreements 
regarding quality ratings will be resolved by discussion 
with a third researcher.
data analysis
To summarise findings, a descriptive approach will be 
taken that will include tables to characterise key features, 
findings, and variations of the research, supplemented 
with graphics (eg, funnel plots) to highlight diver-
sity in study results and other aspects. Guidance from 
the Cochrane Handbook will be followed.33 Because 





















pen: first published as 10.1136/bm





4 Badenes R, et al. BMJ Open 2020;10:e033913. doi:10.1136/bmjopen-2019-033913
Open access 
overlapping individual studies, we will not perform a 
separate meta- analysis of pooled effect estimates. Instead, 
we will perform a systematic narrative (qualitative) 
synthesis or summary for each outcome and intervention 
reporting the pooled treatment effects from the most 
comprehensive and highest- quality meta- analyses (eg, 
high and moderate quality meta- analyses as assessed by 
the AMSTAR-2 approach31). We will provide a narrative 
summary of the quality assessment of the included meta- 
analyses, which will be supported by a table showing the 
results of the critical appraisal. In addition, the narrative 
synthesis will explore the relationship and findings both 
within and between the included meta- analyses.
In exploring the rationale for variations or discrepancies 
in findings between published meta- analyses, several strate-
gies will be employed. First, comparison of methods will be 
performed in relation to eligibility criteria (eg, assessment 
of potential differences in criteria used to identify eligible 
patients, study designs and outcomes), literature search 
details (eg, databases, dates and key differences in search 
strategies), outcome definitions used, statistical approaches 
to meta- analysis and rigour of methods (as reflected by 
potential variations in AMSTAR-2 assessments31). Second, 
the evidence base included in different meta- analyses and 
systematic reviews will be mapped in terms of their degree 
of overlap. This will involve comparison of date ranges of 
studies covered, the numbers of studies and patients across 
meta- analyses and development of a citation matrix to estab-
lish the similarity of included study lists. Third, comparison 
of meta- analysis findings and conclusions drawn by research 
teams will also be performed.
subgroup and sensitivity analyses
In addition to the previously identified pre- planned anal-
yses, we will examine clinical heterogeneity with primary 
neurological diagnosis (eg, ischaemic vs traumatic brain 
injury), disease severity (eg, moderate and severe acute 
brain injury) and hyperosmolar therapy when given 
in different doses and/or for different durations (eg, 
continuous hyperosmolar therapy vs any use).45 46 If data 
permit, we will also explore methodological heteroge-
neity with type of study designs included (eg, randomised 
controlled trials, observational studies or both).
Confidence in cumulative evidence
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation approach47 48 to 
rate the overall quality of the evidence. We will create an 
adapted summary of findings table based on the methods 
described in the Cochrane Handbook33 to convey key 
information about the effect for each treatment and 
overall confidence in the treatment of effect estimates.
Patient and public involvement
There has been no patient and public involved in setting 
the research question or developing plans for design (or 
implementation) of this study protocol.
EthICs And dIssEMInAtIOn
This manuscript outlines a study protocol for an umbrella 
review that will undertake secondary data analysis and 
hence does not require ethical approval. The purpose of 
this study will be to provide an evidence synthesis to iden-
tify which hyperosmolar solutions for treating acute brain 
injury would be supported by most convincing evidence. 
The study findings will be disseminated through presen-
tations at clinical conferences and publication in a peer- 
reviewed journal. Any amendments made to this protocol 
when conducting the analyses will be outlined and 
reported in the final manuscript. All data underlying the 
findings reported in the final manuscript will be depos-
ited in a cross- disciplinary public repository such as the 
Open Science Framework (https:// osf. io/ mcqpv).
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